ResearcherMayo ClinicActive in the last 2 years
Rahul Pannala
Matched on ORCID iD 0000-0001-8189-0655; OpenAlex author ID A5026977929. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 2 papers
Papers 7
- The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. Co-author DOI 10.1002/jso.70361↗
- From Routine Imaging to Risk Stratification: Multimodal Vision-Language Survival Modeling for Pancreatic Cancer. Co-author DOI 10.1109/ichi69079.2026.00071↗
- Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Co-author DOI 10.14309/ctg.0000000000000414↗
- Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. Co-author DOI 10.1016/j.cgh.2019.07.017↗
- Familial pancreatic cancer risk: a population-based study in Utah. Co-author DOI 10.1007/s00535-019-01597-3↗
- Pancreatitis before pancreatic cancer: clinical features and influence on outcome. Co-author DOI 10.1097/mcg.0b013e3182a9f879↗
- Afferent limb syndrome and delayed GI problems after pancreaticoduodenectomy for pancreatic cancer: single-center, 14-year experience. Co-author DOI 10.1016/j.gie.2011.04.029↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Douglas O. Faigel · 4 shared papers, 2014–2021 · strength 0.32
- Paper Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universa… DOI 10.14309/ctg.0000000000000414↗
- Paper Familial pancreatic cancer risk: a population-based study in Utah. DOI 10.1007/s00535-019-01597-3↗
- Paper Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. DOI 10.1016/j.cgh.2019.07.017↗
- Zhi Ven Fong · 1 shared paper, 2026 · strength 0.29
- Nabil Wasif · 1 shared paper, 2026 · strength 0.29
- Yu-Hui H. Chang · 1 shared paper, 2026 · strength 0.29
- Patricia G Lu · 1 shared paper, 2026 · strength 0.29
- Chee‐Chee Stucky · 1 shared paper, 2026 · strength 0.29
- Imon Banerjee · 1 shared paper, 2026 · strength 0.26
- David Le · 1 shared paper, 2026 · strength 0.26
- Niloy Jewel Samadder · 2 shared papers, 2019–2021 · strength 0.20
- Mitesh J. Borad · 1 shared paper, 2021 · strength 0.11
- Daniel H. Ahn · 1 shared paper, 2021 · strength 0.11
- Lisa A. Boardman · 1 shared paper, 2021 · strength 0.11
- Douglas L. Riegert‐Johnson · 1 shared paper, 2021 · strength 0.11
- Mohamad Bassam Sonbol · 1 shared paper, 2021 · strength 0.11
- Tanios Bekaii‐Saab · 1 shared paper, 2021 · strength 0.11
- Pedro Luiz Serrano Usón · 1 shared paper, 2021 · strength 0.11
- Randall W. Burt · 1 shared paper, 2019 · strength 0.09
- Divyanshoo Rai. Kohli · 1 shared paper, 2019 · strength 0.09
- Mark D. Topazian · 1 shared paper, 2020 · strength 0.08
- Thomas C. Smyrk · 1 shared paper, 2020 · strength 0.08
- Douglas W. Mahoney · 1 shared paper, 2020 · strength 0.08
- Ferga C. Gleeson · 1 shared paper, 2020 · strength 0.08
- Suresh T. Chari · 1 shared paper, 2020 · strength 0.08
- Gloria M. Petersen · 1 shared paper, 2020 · strength 0.08
- Shounak Majumder · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.